Table 1 |
|
|
Patient characteristic at baseline. |
|
|
Active LN* (n = 47) |
|
|
|
|
|
Age, years |
|
|
Mean ± SE |
32.90 ± 1.29 |
|
Range, years |
26-39 |
|
Sex, number |
|
|
Female |
50 (96) |
|
Duration of SLE, years |
|
|
Mean ± SE |
5.90 ± 0.62 |
|
Renal-SLEDAI score‡ |
|
|
Median |
12 |
|
Range |
8-12 |
|
Prednisone use, number (%) |
47 (90) |
|
Median dosage, mg/day |
16.00 |
|
Dosage range, mg/day |
7.5-50 |
|
Immunosuppressive drug use |
|
|
Intravenous methylprednisolone |
3 |
|
Intravenous cyclophosphamide |
6 |
|
Mycophenolate mofetil |
6 |
|
Azathioprine |
1 |
|
Hydroxychloroquine |
2 |
|
Extrarenal manifestation, number (%) |
12 (23) |
|
BLyS, ng/mla |
1.32 ± 0.15 |
|
APRIL, ng/mla |
4.10 ± 0.30 |
|
Serum creatinine, mg/dl |
1.06 ± 0.08 |
|
Proteinuria, g/day Urinary erythrocyte count, per high power field |
3.59 ± 0.31 50.84 ± 11.96 |
|
Immunological parametersa |
|
|
C3 (normal range: 70-140 mg/dL) |
60.86 ± 6.05, |
|
ANA, titer |
731.20 ± 606.29 |
|
Anti-dsDNA, titer |
351.74 ± 73.76 |
|
Histological parameters |
|
|
Activity score |
7.83 ± 0.70 |
|
Chronicity score |
3.01 ± 0.37 |
|
|
|
|
*Includes only lupus nephritis class III or IV by ISN/RPS 2003 criteria, ‡ renal-SLEDAI (Systemic Lupus Erythematosus Disease Activity Score) uses four endpoints as follows: UPCI or 24-hour urine protein ≥0.5 g/day, urinary RBCs ≥5/HPF, urinary WBCs ≥5/HPF and urinary cellular casts ≥1/HPF; and the maximal point was set at 16. aData are expressed as mean ± SE. ANA, antinuclear antibody; APRIL, a proliferation-inducing ligand; BlyS, B lymphocyte activation protein; HPF, high power field; LN, lupus nephritis; RBC, red blood cells; SLE, systemic lupus erythematous; WBC, white blood cells. |
|
|
Treamtrakanpon et al. Arthritis Research & Therapy 2012 14:R252 doi:10.1186/ar4095 |
|
